Related Experiment Video
Updated: May 20, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
An Algorithm for the Preclinical Screening of Anticancer Drugs Effective against Brain Tumors
1Department of Clinical Neuroscience, Karolinska University Hospital, Karolinska Institute, SE-141 86 Stockholm, Sweden.
Abstract:
The anticancer drugs screening program is a long and expensive process. It is estimated that only 5% of drugs entering clinical trials are approved by the FDA. Moreover, many of the drugs that enter clinical trials are often of limited use in clinical practice, and most cancers remain untreatable. Brain tumors are particularly difficult to treat due to the presence of the blood brain barrier that limits the penetration of anticancer drugs. Additionally the isolation from most brain tumors of putative cancer stem cells and novel models of cancer stem cell biology suggest that anticancer drugs should be delivered for prolonged time and at higher concentrations to deplete any potential tumorigenic cell. In this paper, current concepts of cancer stem cell biology and novel concepts of anticancer drugs screening are integrated to develop a seven-steps algorithm as a guideline for the preclinical evaluation of active compounds for the treatment of brain tumors. The flexibility of the algorithm allows the inclusion of alternative studies to exhaustively investigate anticancer drugs and creates multiple opportunities where decisions to engage or not in early clinical trials can be made providing a useful tool for translational research in neurooncology.
Insights
Developing a new algorithm improves anticancer drug screening for brain tumors. This seven-step guideline aids preclinical evaluation, enhancing drug development for neuro-oncology and potentially increasing treatment success rates.
Area of Science:
- Neuro-oncology
- Cancer Stem Cell Biology
- Translational Research
Background:
- Anticancer drug screening is lengthy, costly, with low FDA approval rates (5%).
- Many approved drugs have limited clinical utility, leaving most cancers untreatable.
- Brain tumors present unique challenges, including the blood-brain barrier and the need for prolonged, high-concentration drug delivery to target cancer stem cells.
Purpose of the Study:
- To integrate cancer stem cell biology and novel drug screening concepts.
- To develop a structured, seven-step algorithm for preclinical evaluation of brain tumor therapeutics.
- To provide a flexible tool for decision-making in early clinical trial engagement.
Main Methods:
- Integration of current cancer stem cell biology knowledge.
- Incorporation of novel anticancer drug screening methodologies.
- Development of a seven-step preclinical evaluation algorithm.
Main Results:
- A flexible seven-step algorithm for preclinical evaluation of brain tumor compounds.
- Multiple decision points for early clinical trial consideration.
- A framework to address challenges in brain tumor drug development.
Conclusions:
- The proposed algorithm offers a systematic approach to preclinical evaluation for brain tumor treatments.
- It facilitates translational research in neuro-oncology by optimizing drug candidate selection.
- Enhances the efficiency and potential success rate of developing novel anticancer drugs for brain tumors.
